Therapure Biopharma Acquire Plasma Protein Purification Technology from Upfront Chromatography
Therapure Biopharma (Ontario, Canada) has entered into an agreement with Upfront Chromatography (Copenhagen, Denmark) to acquire assets and associated business related to human plasma fractionation from Upfront. As part of the deal Therapure will acquire proprietary protein purification technology based on expanded bed chromatography, along with exclusive rights to commercialize the technology.
Therapure Biopharma (Ontario, Canada) has entered into an agreement with Upfront Chromatography (Copenhagen, Denmark) to acquire assets and associated business related to human plasma fractionation from Upfront. As part of the deal Therapure will acquire proprietary protein purification technology based on expanded bed chromatography, along with exclusive rights to commercialize the technology.
Nick Green, CEO of Therapure, said: “ Therapure has established an excellent reputation as a biologics contract development and manufacturing organization (CDMO) with integrated services including plasma protein purification. The acquisition of this technology will further support Therapure’s reputation as a leader in the biologics manufacturing sector in general, and as a global leader in terms of plasma protein purification.” He added: “We feel strongly that this technology can add significant value to our clients as they seek to optimize their manufacturing processes and associated economics.”
Upfront divested their pharmaceutical business in April 2010 to DSM Biologics, and is now focused on technology developed for the food/feed ingredients business for the extraction of food grade ingredients.
Michael Pålsson, CEO of Upfront, said: “We see this additional divestment of our technology to Therapure as a major milestone for Upfront. It is yet another significant blue-stamp of our technology, driven by its value creation in the capture of high value proteins. We are now ready to focus 100% on our BioMine business which aims to valorize under-utilized side and waste streams from the food, feed, and biofuel industries.” He added: “There is a broad range of food and feed industries in the world with large volumes of side and waste streams containing valuable proteins. We are able to help these manufacturers get more value out of these streams, and at the same time we see a growing, global need for alternative protein sources to feed the world’s population.”
For more information please visit:
www.therapurebio.com
LC–MS/MS-Based System Used to Profile Ceramide Reactions to Diseases
April 26th 2024Scientists from the University of Córdoba in Córdoba, Spain recently used liquid chromatography–tandem mass spectrometry (LC–MS/MS) to comprehensively profile human ceramides to determine their reactions to diseases.
Inside the Laboratory –– Women in Separation Science Edition
April 25th 2024Inside the Laboratory is a joint series with LCGC and Spectroscopy, profiling analytical scientists and their research groups at universities all over the world. This series spotlights the current chromatographic and spectroscopic research their groups are conducting, and the importance of their research in analytical chemistry and specific industries. In this “Inside the Laboratory –– Women in Separation Science” special edition PDF, we profile four industry leaders and the impact that their research is having in specific fields such as environmental analysis, forensics, national security, and drug development.
